Provided is an ink composition less likely to cause offset and sticking. Provided is a printed matter and a printing method using such ink composition. The ink composition includes a (meth) acrylic resin and a drying oil, the (meth)acrylic resin: containing at least 40% by weight or more of a structural unit derived from (meth)acryl monomer having a straight-chain alkyl group having 4 or more carbon atoms, branched alkyl group having 4 or more carbon atoms, or cyclic alkyl group having 4 or more carbon atoms (1); having a glass transition temperature of 63° C. to 180° C. (2); and having a weight-average molecular weight of 1000 to 80,000 (3).

Provided is an ink composition less likely to cause offset and sticking. Provided is a printed matter and a printing method using such ink composition. The ink composition includes a (meth) acrylic resin and a drying oil, the (meth)acrylic resin: containing at least 40% by weight or more of a structural unit derived from (meth)acryl monomer having a straight-chain alkyl group having 4 or more carbon atoms, branched alkyl group having 4 or more carbon atoms, or cyclic alkyl group having 4 or more carbon atoms (1); having a glass transition temperature of 63° C. to 180° C. (2); and having a weight-average molecular weight of 1000 to 80,000 (3).

Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

The disclosure is directed to compounds of Formula I ##STR00001##
Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

The disclosure is directed to compounds of Formula I ##STR00001##
Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.

Provided herein are methods for treating uveal melanoma in a subject in need thereof by administering an effective amount of an agent that inhibits expression of FAK protein to the subject. In one aspect, the agent that inhibits expression of FAK protein comprises, or alternatively consists essentially of, or yet further consists of a gene editing agent, such as for example one or more of: RNA interference (RNAi), CRISPR/Cas, ZFN, and/or TALEN. In another aspect, the agent is VS-4718. Also described herein are kits comprising, or alternatively consisting essentially of, or yet further consisting of one or more of: agents that inhibit expression of FAK protein, siRNAs, shRNAs, miRNAs, nucleases and/or guide RNA sequences for carrying out the methods of this disclosure, and optional instructions for use.

Provided herein are methods for treating uveal melanoma in a subject in need thereof by administering an effective amount of an agent that inhibits expression of FAK protein to the subject. In one aspect, the agent that inhibits expression of FAK protein comprises, or alternatively consists essentially of, or yet further consists of a gene editing agent, such as for example one or more of: RNA interference (RNAi), CRISPR/Cas, ZFN, and/or TALEN. In another aspect, the agent is VS-4718. Also described herein are kits comprising, or alternatively consisting essentially of, or yet further consisting of one or more of: agents that inhibit expression of FAK protein, siRNAs, shRNAs, miRNAs, nucleases and/or guide RNA sequences for carrying out the methods of this disclosure, and optional instructions for use.